BioSpace News Archive

A pre-specified exploratory analysis from the SURPASS-4 trial showed tirzepatide, a novel once-weekly medication for the treatment of diabetes, improved kidney outcomes for adults with type 2 diabetes who have increased cardiovascular risk.

Atara Biotherapeutics, Inc. reported the grant of an aggregate of 126,928 restricted stock units of Atara’s common stock to four newly hired employees and stock options to purchase an aggregate of 186,378 shares of Atara’s common stock to three such newly hired employees.

AIkido Pharma, Inc., announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 17.

Immune Therapeutics, Inc. (OTC:BB IMUN), today announced that it will expand its Board of Directors from two to five members.

Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that David Marek, Chief Executive Officer and Uneek Mehra, Chief Financial and Business Officer of Myovant Sciences, Inc., will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Thursday, June 16, 2022.

Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma .

Intensity Therapeutics, Inc. announced that data from its ongoing phase 1/2 clinical trial demonstrating the efficacy and tolerability of INT230-6, either as monotherapy or in combination with pembrolizumab in patients with relapsed, refractory and metastatic solid tumors, will be presented on June 5, at the 2022 American Society of Clinical Oncology Annual Meeting being held in Chicago and virtually from June 3-7, 2022.

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 12:45 p.m. ET.

Michele Janis Appointed Acting Chief Financial Officer Anthony Krick Appointed Vice President & Chief Accounting Officer.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the company will present clinical trial design details for three of its wholly-owned investigative therapies, NX-2127, DeTIL-0255 and NX-1607, each currently in Phase 1 development, at the Annual Meeting of the American Society of Clinical Oncology (ASCO).